跳到正文
原文
GEN Genetic Engineering & Biotech· Kathy Vuksanaj·· 13 天前AI 评分35

《衰老蛋白质组:时钟、队列与临床试验》

The Aging Proteome: Clocks, Cohorts, and Clinical Trials

AI 导读

在GEN webinar中,Michael Corley博士介绍了衰老研究受限于证据而非想法,分享了随机对照试验中semaglutide对心血管代谢和炎症蛋白的影响,以及XPRIZE Healthspan全球竞赛的样本库。Xiao-Jun Ma博士则展示了跨三个队列识别的蛋白质组模块,该模块与死亡率、认知能力和共病负担相关,并探讨了蛋白质组衰老加速的时间点。

正文

Panelists:

Image of Xiao-Jun Ma, PhD

Xiao-Jun Ma, PhD

Chief Technology Officer
Alamar Biosciences

Panelist

Image of Xiao-Jun Ma, PhD

Xiao-Jun Ma, PhD

Xiao-Jun Ma, PhD, joined Alamar Biosciences in June of 2021 as chief technology officer. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Most recently he served as vice president and chief scientific officer in the Genomics Division of Bio-Techne. During his 11-year tenure at ACD, Ma led the development of a portfolio of in situ RNA and DNA detection solutions for research and clinical diagnostics markets. Prior to joining ACD, he was vice president of R&D/biostatistics at bioTheranostics. Before bioTheranostics, Ma held senior bioinformatics positions at Johnson & Johnson and Monsanto/Searle (Pfizer), where he applied his multi-disciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.

Image of Michael J. Corley, PhD

Michael J. Corley, PhD

Tenured Assoc. Professor of Medicine
University of California, San Diego

Panelist

Image of Michael J. Corley, PhD

Michael J. Corley, PhD

Michael J. Corley, PhD, is an associate professor in medicine within the Division of Geriatrics, Gerontology, & Palliative Care and The Stein Institute for Research on Aging. He received his undergraduate degree from UCSD, an MA and PhD in behavioral neuroscience from the University of Hawaii, and completed postdoctoral training at the John A. Burns School of Medicine in epigenetics, immunology, and infectious diseases. Corley leads a global epigenetics research program focusing on understanding the interplay between the immune system, viruses, and aging. His laboratory is at the forefront of generating critical data to advance the development, validation, and implementation of novel biomarkers and therapeutics aimed at promoting longevity.

Broadcast Date: Tuesday, December 1, 2026

  • Time: 08:00 PST, 11:00 EST, 16:00 GMT

Geroscience proposes that slowing the biology of aging could delay many chronic diseases at once. Testing that idea requires biomarkers that are precise, reproducible, and responsive to intervention.

In this GEN webinar, two experts will show how ultra-sensitive, multiplexed proteomics can measure both the pace of aging and the effects of interventions designed to change it. In his talk, Michael Corley, PhD, will explain why the aging field is limited less by ideas than by evidence, and how completed clinical trials with banked samples can be used to screen candidate interventions quickly. He will share proteomic and epigenetic findings from a randomized trial of semaglutide, including cardiometabolic and inflammatory protein changes during treatment and after the drug is stopped. He will also describe XPRIZE Healthspan, a global competition whose central biorepository will hold samples from 20 intervention trials.

Then Xiao-Jun Ma, PhD, will present a data-driven proteomic module identified across three cohorts that tracks biological aging. He will show how a clock built from this module relates to mortality, cognition, and comorbidity burden, how it compares with DNA methylation clocks, and what it reveals about when proteomic aging accelerates. Key takeaways include:

  • Why evidence, not ideas, is the bottleneck in geroscience, and how completed trials can help close the gap
  • How proteomic measurements capture intervention effects that epigenetic clocks may miss
  • How an intrinsic, unsupervised protein module can serve as a portable measure of biological aging
  • What large, harmonized trial biorepositories mean for biomarker discovery in aging research

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

Produced with support from:

Alamar Biosciences Logo

The post The Aging Proteome: Clocks, Cohorts, and Clinical Trials appeared first on GEN - Genetic Engineering and Biotechnology News.

来源:GEN Genetic Engineering & Biotech · genengnews.com